Evolus, Inc. Common Stock (EOLS) concentration risks

Evolus's concentration risk is entirely supply-side and entirely dependency in character — both disclosed exposures carry a high share, and both concern single-source manufacturing relationships behind the company's two key product lines. Daewoong Pharmaceuticals manufactures and supplies Jeuveau to the company, while Symatese Aesthetics manufactures and supplies Evolysse. Neither claim comes with a percentage, so the dollar or revenue impact isn't quantifiable from the filing, but the qualitative framing is unambiguous: these are single-named third-party manufacturers standing behind the company's core commercial products, with no disclosed alternate source for either. Because both relationships sit at the same high disclosed share, there's no clear "larger vs. smaller" ordering between them — the risk is duplicated rather than diversified, since a disruption at either Daewoong or Symatese would directly affect a distinct product line rather than being absorbed elsewhere in the business. This is a structurally idiosyncratic risk profile: both exposures are dependency-type, tied to identifiable counterparties, not macro or geographic in nature. For an investor, the read-through is that Evolus's manufacturing base is concentrated in two named partners with no disclosed backup, making single-partner continuity the central supply-side variable to watch.

For the engine’s reasoning on EOLS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.